- Home
- FRPH vs CRGX Comparison
FRPH vs CRGX Comparison
Compare FRPH & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRPH
- CRGX
- Stock Information
- Founded
- FRPH 1986
- CRGX 2021
- Country
- FRPH United States
- CRGX United States
- Employees
- FRPH N/A
- CRGX N/A
- Industry
- FRPH Real Estate
- CRGX
- Sector
- FRPH Finance
- CRGX
- Exchange
- FRPH Nasdaq
- CRGX Nasdaq
- Market Cap
- FRPH 537.7M
- CRGX 190.0M
- IPO Year
- FRPH N/A
- CRGX 2023
- Fundamental
- Price
- FRPH $27.18
- CRGX $4.16
- Analyst Decision
- FRPH
- CRGX Hold
- Analyst Count
- FRPH 0
- CRGX 7
- Target Price
- FRPH N/A
- CRGX $4.67
- AVG Volume (30 Days)
- FRPH 52.6K
- CRGX 586.4K
- Earning Date
- FRPH 08-06-2025
- CRGX 08-11-2025
- Dividend Yield
- FRPH N/A
- CRGX N/A
- EPS Growth
- FRPH 12.32
- CRGX N/A
- EPS
- FRPH 0.36
- CRGX N/A
- Revenue
- FRPH $31,576,000.00
- CRGX N/A
- Revenue This Year
- FRPH N/A
- CRGX $57.81
- Revenue Next Year
- FRPH N/A
- CRGX N/A
- P/E Ratio
- FRPH $76.63
- CRGX N/A
- Revenue Growth
- FRPH 4.58
- CRGX N/A
- 52 Week Low
- FRPH $25.37
- CRGX $3.00
- 52 Week High
- FRPH $33.00
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- FRPH 48.70
- CRGX 45.07
- Support Level
- FRPH $26.73
- CRGX $4.33
- Resistance Level
- FRPH $27.71
- CRGX $4.36
- Average True Range (ATR)
- FRPH 0.61
- CRGX 0.19
- MACD
- FRPH -0.00
- CRGX -0.04
- Stochastic Oscillator
- FRPH 24.41
- CRGX 21.76
About FRPH FRP Holdings Inc.
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.